Call us now on: +44 (0) 1223 743170
Domainex is developing an oncology-focussed pipeline of novel drug compounds. We have chosen a number of well-validated but challenging targets, that we have successfully unlocked with our Combinatorial Domain Hunting and LeadBuilder technologies. The pipeline is focussed upon some exciting kinases and on lysine methyltransferases (KMTs) involved in epigenetics,
We intend to take these projects into lead optimization and candidate selection, and would welcome enquiries from collaborators who may be interested in working with us on their further development.
Target |
Target expression |
Assay |
Crystal Structure |
Hit ID |
H2L |
Lead Optimisation |
Candidate Drug Nomination |
|---|---|---|---|---|---|---|---|
| TBK1/IKKε |  |
|
|
|
|
Expected in early 2012 | |
| KMT target 1 (G9a) | |
|
|
|
|
||
| KMT target 2 (MLL2) | |
|
|
||||
| KMT target 3
|
|
|